Shares of Lipocine Inc (NASDAQ:LPCN) saw an uptick in trading volume on Tuesday . 6,915,549 shares changed hands during mid-day trading, an increase of 642% from the previous session’s volume of 931,555 shares.The stock last traded at $2.25 and had previously closed at $2.18.

A number of brokerages have weighed in on LPCN. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Lipocine in a research report on Monday. ValuEngine cut Lipocine from a “hold” rating to a “sell” rating in a research report on Thursday, December 6th. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating on shares of Lipocine in a research report on Thursday, January 17th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $4.83.

The stock has a market cap of $49.31 million, a price-to-earnings ratio of -3.98 and a beta of 0.68. The company has a debt-to-equity ratio of 0.73, a current ratio of 4.63 and a quick ratio of 4.63.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Wednesday, March 6th. The specialty pharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). As a group, equities analysts expect that Lipocine Inc will post -0.53 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in Lipocine by 145.8% in the third quarter. JPMorgan Chase & Co. now owns 95,429 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 56,606 shares during the period. Vanguard Group Inc grew its position in Lipocine by 4.9% in the third quarter. Vanguard Group Inc now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after acquiring an additional 35,000 shares during the period. Finally, Vanguard Group Inc. grew its position in Lipocine by 4.9% in the third quarter. Vanguard Group Inc. now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after acquiring an additional 35,000 shares during the period. Hedge funds and other institutional investors own 9.82% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Lipocine (LPCN) Sees Unusually-High Trading Volume” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2019/03/14/lipocine-lpcn-sees-unusually-high-trading-volume.html.

Lipocine Company Profile (NASDAQ:LPCN)

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Recommended Story: Conference Calls and Individual Investors

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.